Autoimmune Targets, Solid Tumor Dosing, And ALLOHA Data Keep TCRX In Focus

Clinical-stage biotech company TScan Therapeutics Inc. (TCRX) is emerging as an interesting biotech name to watch, with fresh momentum across both its autoimmune and oncology programs.

Company Overview

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com